Evaluation of Magnesium Carbonate Effectiveness and Safety in Hyperphophatemia Patients on Chronic Hemodialysis

Document Type : Original Article (s)

Authors

1 Student of Medicine, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Magnesium salts bind dietary phosphorus, but their use in renal patients is limited due to their potential side effects. The aim of this study was to evaluate the efficacy and safety of magnesium carbonate (MgCO3) as a phosphate binder in hemodialysis patients.Methods: Forty one stable hemodialysis patients were randomly allocated to receive either MgCO3 (n = 20) or calcium carbonate (CaCO3), (n = 21) for 6 weeks.Findings: All of the patients finished the study. Mean calcium level was 8.51 mg/dl and 9.1 mg/dl in MgCo3 and CaCo3 groups respectively (P < 0.05). The mean serum albumin was higher in the trial group in the 6th week (P < 0.001). There were no significant differences in BP, lipid profile, serum phosphorus and CRP levels between the two groups.Conclusion: Our study shows that MgCO3, administered for a period of 6 weeks, is an effective and inexpensive agent in controlling serum phosphate levels in hemodialysis patients.

Keywords

References

  1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945-53.
  2. Liu KD, Chertow GM. Dialysis in the treatment of renal failure. In: Fauci AS, Eugene B, Hauser SL, Longo DL, J J, editors. Harrison's principles of internal medicine. 17th ed. New York, NY: Mc Graw Hill; 2008. p. 1772.
  3. Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p 591-5.
  4. Felsenfeld AJ, Rodriguez M. Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 1999; 10(4): 878-90.
  5. Wei M, Esbaei K, Bargman J, Oreopoulos DG. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review. Perit Dial Int 2006; 26(3): 366-73.
  6. Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37(1 Suppl 2): S66-S70.
  7. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez CL, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9(10): 1845-52.
  8. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int 1993; 43(2): 436-42.
  9. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl 2004; (90): S25-S32.
  10. Salusky IB. A new era in phosphate binder therapy: what are the options? Kidney Int Suppl 2006; (105): S10-S15.
  11. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996; 49(1): 163-7.
  12. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20(5): 1262-75.
  13. Proudfoot D, Shanahan CM, Weissberg PL. Vascular calcification: new insights into an old problem. J Pathol 1998; 185(1): 1-3.
  14. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342(20): 1478-83.
  15. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32(2): 260-5.
  16. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1-130.
  17. De Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25(11): 3707-17.
  18. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71(5): 438-41.
  19. Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008; 40(1): 193-201.
  20. Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol 1991; 53: 299-307.
  21. Truttmann AC, Faraone R, Von Vigier RO, Nuoffer JM, Pfister R, Bianchetti MG. Maintenance hemodialysis and circulating ionized magnesium. Nephron 2002; 92(3): 616-21.
  22. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37(6): 1267-76.
  23. Towler DA, Shao JS, Cheng SL, Pingsterhaus JM, Loewy AP. Osteogenic regulation of vascular calcification. Ann N Y Acad Sci 2006; 1068: 327-33.
  24. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4): 607-17.
  25. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010; 56(3): 453-62.
  26. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32(3): 388-94.
  27. Izawa H, Imura M, Kuroda M, Takeda R. Proceedings: Effect of magnesium on secondary hyperparathyroidism in chronic hemodialysis: a case with soft tissue calcification improved by high Mg dialysate. Calcif Tissue Res 1974; 15(2): 162.
  28. Marken PA, Weart CW, Carson DS, Gums JG, Lopes-Virella MF. Effects of magnesium oxide on the lipid profile of healthy volunteers. Atherosclerosis 1989; 77(1): 37-42.
  29. Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 2003; 24(1-3): 107-36.
  30. Meuwese CL, Halbesma N, Stenvinkel P, Dekker FW, Molanaei H, Qureshi AR, et al. Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. Nephrol Dial Transplant 2010; 25(11): 3717-23.
  31. Mazur A, Maier JA, Rock E, Gueux E, Nowacki W, Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 2007; 458(1): 48-56.
Journal of Isfahan Medical School
Volume 29, Issue 163 - Serial Number 163
September and October 2012
Pages 2033-2047

Files

History

  • Receive Date: 20 June 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics